The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia

Journal of Clinical Oncology

Volumn 19, Issue 18 SUPPL., 2001, Pages

  Arteaga, C L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

CONFERENCE PAPER; ENDOCYTOSIS; ERYTHROBLASTOSIS; GENE ACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LIGAND BINDING; MUTANT; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ADENOSINE TRIPHOSPHATE; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0035884231     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (93)

1. Cell signaling by receptor tyrosine kinases
2. Untangling the erbB signalling network
3. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
4. The erbB signaling network: Receptor heterodimerization in development and cancer
5. ErbB, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signalling
6. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signalling superiority to receptor heterodimers
7. Efficient coupling of phosphatidylinositol 3-kinase, but not phospholipase C-gamma or GTPase-activating protein distinguishes ErbB3 signalling from that of other ErbB/EGFR family members
8. Diversification of neu differentiation factor and epidermal growth factor signalling by combinatorial receptor interactions
9. C-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor
10. All erbB receptors other than epidermal growth factor receptor are endocytosis impaired
11. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype
12. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
13. A strain-independent postnatal degeneration in mice lacking the EGF receptor
14. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
15. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes
16. Trans-activation of the epidermal growth factor receptor gene by the hepatitis B virus X-gene product
17. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor
18. Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast
19. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice
20. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
21. Synergistic interaction of the neu proto-oncogene and TGF alpha in the mammary epithelium of transgenic mice
22. Epidermal growth factor-related peptides and their receptors in human malignancies
23. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
24. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review of 5232 patients
25. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
26. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer
27. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers
28. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the lung
29. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
30. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo
31. Evaluation of epidermal growth factor-related growth factors and receptors and or neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel density are independent prognostic indicators of survival
32. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma
33. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
34. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones, and interactions with neu
35. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-alpha in the progression of prostatic neoplasms
36. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
37. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
38. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
39. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer
40. Patterns of epidermal growth factor receptor amplification in malignant gliomas
41. Structural alterations of the epidermal growth factor receptor gene in human gliomas
42. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
43. The epidermal growth factor receptor and its inhibition in cancer therapy
44. Mice with a null mutation of the TGF alpha gene have normal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation
45. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development
46. Anti-oncogenic activity of signaling-defective epidermal growth factor receptor mutants
47. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
48. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A 431 squamous carcinoma cells
49. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
50. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
51. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck
52. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
53. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects
54. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
55. Differentiation or immune destruction: Two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor
56. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous lung carcinomas
57. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
58. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
59. Development of inhibitors for protein tyrosine kinases
60. Tyrosine kinase inhibitors: 17. Irreversible inhibitors of the epidermal growth factor receptor - 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
61. Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD158780 and a new irreversible inhibitor PD183805
62. ZD1839 ('Iressa') as an anticancer agent
63. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase
64. Combinatorial chemoprevention of intestinal neoplasia
65. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
66. GW2016, a dual inhibitor of erbB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries and in vivo anti-tumor activity
67. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
68. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
69. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
70. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852
71. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
72. Potent anti-tumor activity of ABX-EGF, a fully human monoclonal antibody to epidermal growth factor receptor
73. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model of human melanoma
74. K1P1
75. K1P1 and induces G 1 arrest in prostate cancer cell line DU145
76. K1P1 independent of MAPK activity
77. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB-2) overexpressing breast tumor cells
78. Blockade of the EGF receptor tyrosine kinase suppresses tumorigenesis in MMTV/ neu + MMTV/TGF alpha bigenic mice
79. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
80. Augmentation of a humanized anti-HER-2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
81. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish transformation
82. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
83. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways
84. Signal characteristics of G protein-transactivated EGF receptor
85. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
86. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
87. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
88. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
89. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts
90. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
91. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody
92. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathways in carcinoma cells, leading to increased proliferation and protection from apoptosis
93. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells